Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526785 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
A Phase 4 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 4
- Development phase
- 113
- Enrollment target
NCT01526785 is a Phase 4 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 113 participants.
The verdict
NCT01526785, a Phase 4 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 113 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the efficacy and safety of treatment with 4000 litre (L) alglucosidase alfa (Lumizyme®) in Pompe participants.
Interventions
- DRUG Alglucosidase alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01526785
The ClinicalTrials.gov registry entry for NCT01526785 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alglucosidase alfa is the first listed.
NCT01526785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01526785 about?
NCT01526785 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease". The objective of this study was to evaluate the efficacy and safety of treatment with 4000 litre (L) alglucosidase alfa (Lumizyme®) in Pompe participants.
What is the current status of trial NCT01526785?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 113 participants. The study started on 2012-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01526785?
The interventions under investigation include: Alglucosidase alfa (DRUG).
Who is sponsoring clinical trial NCT01526785?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.